Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Decline in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 42,034 shares, a drop of 35.9% from the July 30th total of 65,538 shares. Based on an average trading volume of 28,832 shares, the short-interest ratio is currently 1.5 days. Approximately 0.8% of the shares of the company are short sold.

Neuphoria Therapeutics Stock Up 0.4%

NASDAQ:NEUP traded up $0.01 during trading hours on Tuesday, hitting $3.77. 9,516 shares of the company’s stock traded hands, compared to its average volume of 103,963. Neuphoria Therapeutics has a 52 week low of $3.19 and a 52 week high of $21.40. The business’s fifty day simple moving average is $3.80 and its two-hundred day simple moving average is $4.36. The firm has a market cap of $20.38 million, a P/E ratio of -0.34 and a beta of 0.75.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on NEUP. Wall Street Zen upgraded Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday. Finally, HC Wainwright lowered Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Neuphoria Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $21.00.

Institutional Trading of Neuphoria Therapeutics

A number of large investors have recently modified their holdings of the business. AdvisorShares Investments LLC increased its position in shares of Neuphoria Therapeutics by 129.1% in the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock worth $521,000 after purchasing an additional 75,631 shares during the last quarter. Ikarian Capital LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter valued at approximately $184,000. ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics during the second quarter valued at approximately $131,000. Diadema Partners LP lifted its position in Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock valued at $194,000 after purchasing an additional 28,548 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Neuphoria Therapeutics in the 3rd quarter worth approximately $216,000. Institutional investors own 15.90% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.